All

Seventure Partners Life Sciences Investing Update – H2 2017
18 January 2018

Seventure Partners Life Sciences Investing Update – H2 2017

“2017 ended on a high note. Our Health For Life Capital™ investment vehicle has backed some truly remarkable disruptive technologies over the second half of the year and...

Read the press release
Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome
7 December 2017

Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome

VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has recieved Orphan Drug designation from the US FDA for C. difficile...

Read the press release
Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy
1 December 2017

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy

New collaborations with Leiden University Medical Center and the Mitchell Cancer Institute focused on melanoma and cancers of the bladder, head and neck, and kidneys

Read more
Scipio bioscience announces its seed funding of €1.2m obtained from Seventure Partners’ Quadrivium I seed fund and High-Tech Gründerfonds
14 November 2017

Scipio bioscience announces its seed funding of €1.2m obtained from Seventure Partners’ Quadrivium I seed fund and High-Tech Gründerfonds

Scipio bioscience, a Paris-based biotechnology company devoted to providing a novel sample preparation solution for single-cell studies in the form of benchtop kits, announces...

Read the press release
Seventure Partners announces the trade sale of its portfolio company Cambrooke Therapeutics, Inc. to Ajinomoto Co. Inc
10 November 2017

Seventure Partners announces the trade sale of its portfolio company Cambrooke Therapeutics, Inc. to Ajinomoto Co. Inc

Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces the trade sale of...

Read the press release
Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers
30 October 2017

Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers

ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its...

Read the press release
Eligo Bioscience Secures $20 Million Series A from Khosla Ventures and Seventure to Bring Precision Medicine to the Microbiome
26 September 2017

Eligo Bioscience Secures $20 Million Series A from Khosla Ventures and Seventure to Bring Precision Medicine to the Microbiome

Eligo Bioscience, the French microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured a $20 million Series A round of financing from...

Read the press release